P2RY12 and atrial fibrillation: The PIONEER study also supports the results of this current analysis.[21] In their study, the authors showed that among patients with AF who were treated by PCI, administration of a non-vitamin K antagonist, more precisely rivaroxaban 15 mg once daily plus a P2Y12 inhibitor or rivaroxaban 2.5 mg twice daily plus DAPT was associated with reduced bleeding events compared to the standard of care vitamin K antagonist plus DAPT.